Shares in Adamis Pharmaceuticals (NSDQ:ADMP) soared more than 50% yesterday after it won FDA approval for its generic EpiPen emergency allergy pre-filled syringe, sending shares in competitor Mylan (NSDQ:MYL) down -3%.
For years, Mylan has commanded more than 90% of the market for emergency epinephrine injectors.
Get the full story at our sister site, Drug Delivery Business News.